{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ziaunys M"],"funding":["European Commission"],"pagination":["1887"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9598636"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(10)"],"pubmed_abstract":["Amyloidogenic protein/peptide aggregation into fibrillar aggregates is associated with multiple amyloidoses, including widespread neurodegenerative disorders. Despite years of research and a well-understood mechanism, there are still very few treatments available for the increasing number of amyloid-related disorders. In recent years, the search for potential anti-aggregation compounds has shifted toward naturally occurring molecules, with one of the most promising being epigallocatechin-3-gallate (EGCG). This polyphenolic compound was shown to inhibit the aggregation of several amyloidogenic proteins/peptides, including amyloid-beta (related to Alzheimer's disease) and alpha-synuclein (related to Parkinson's disease). However, multiple reports have indicated its limited stability under ph"],"journal":["Antioxidants (Basel, Switzerland)"],"pubmed_title":["Exploring Epigallocatechin-3-Gallate Autoxidation Products: Specific Incubation Times Required for Emergence of Anti-Amyloid Properties."],"pmcid":["PMC9598636"],"funding_grant_id":["293476"],"pubmed_authors":["Ziaunys M","Smirnovas V"],"additional_accession":[]},"is_claimable":false,"name":"Exploring Epigallocatechin-3-Gallate Autoxidation Products: Specific Incubation Times Required for Emergence of Anti-Amyloid Properties.","description":"Amyloidogenic protein/peptide aggregation into fibrillar aggregates is associated with multiple amyloidoses, including widespread neurodegenerative disorders. Despite years of research and a well-understood mechanism, there are still very few treatments available for the increasing number of amyloid-related disorders. In recent years, the search for potential anti-aggregation compounds has shifted toward naturally occurring molecules, with one of the most promising being epigallocatechin-3-gallate (EGCG). This polyphenolic compound was shown to inhibit the aggregation of several amyloidogenic proteins/peptides, including amyloid-beta (related to Alzheimer's disease) and alpha-synuclein (related to Parkinson's disease). However, multiple reports have indicated its limited stability under ph","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2025-04-04T11:29:32.135Z","creation":"2025-04-04T11:29:32.135Z"},"accession":"S-EPMC9598636","cross_references":{"pubmed":["36290609"],"doi":["10.3390/antiox11101887"]}}